Smith & Nephew Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Smith & Nephew Bundle
Download Your Competitive Advantage
The Smith & Nephew BCG Matrix maps its core portfolio—orthopaedics, sports medicine, and advanced wound care—into Stars, Cash Cows, Question Marks, and Dogs to clarify where market leadership and resource drains lie. This snapshot highlights which product lines may warrant further investment versus those that could fund growth. Purchase the full BCG Matrix for a complete breakdown and strategic insights you can act on. Buy the full report to receive a detailed Word analysis plus an Excel summary for quick presentation and decision-making.
Stars
CORI surgical robotics
As of 2024 robotics-assisted knee arthroplasty is a fast-growing segment and CORI gives Smith & Nephew a credible, scaled presence in the space. Installed-base momentum and ASC-friendly workflows sustain high utilization and implant pull-through. Continued software upgrades and indications expansion support share retention as the segment grows. Prioritize investment to defend leadership and convert growth into future cash-cow economics.
PICO single‑use NPWT
PICO single‑use NPWT is a Star for Smith & Nephew: strong clinical support, brand recognition and broad indications have driven leading share in a niche growing at ≈10% CAGR to 2028. Adoption across inpatient-to-home drove robust 2024 volume growth; group sales were £3.1bn in 2024. Continued funding for market development and outcomes evidence keeps PICO first choice; it is supported by >10 RCTs.
Sports medicine soft‑tissue repair
Sports medicine soft-tissue repair (shoulder, knee, hip arthroscopy implants and instruments) is a structural growth category for Smith & Nephew and was a star in 2024. Smith & Nephew leads in suture anchors, fixation, access and RF energy for soft-tissue procedures. High procedure volumes and rapid innovation cadence sustain share and growth, while continual portfolio refresh and surgeon training preserve star status.
REGENETEN bioinductive implant
REGENETEN is a Star: rotator-cuff bioinductive augmentation is scaling fast due to improved outcomes and OR efficiency. REGENETEN, FDA-cleared 2019, has strong surgeon advocacy and brand leadership. With ~250,000 US repairs/year and accelerating 2024 category growth, prioritize evidence and geographic expansion to compound share.
- Surgeon advocacy
- FDA clearance 2019
- ~250k US procedures/year
- Invest RCTs & geographies
OASIS advanced wound matrix
OASIS advanced wound matrix is a Star for Smith & Nephew: biologic collagen matrices are growing faster than traditional dressings. In 2024 OASIS's long clinical heritage and broad reimbursement anchor a strong subsegment share. Utilization is expanding across acute, outpatient and home settings as protocols standardize; ongoing trials and HEOR can support conversion and premium pricing.
- Established clinical heritage
- Broad payer coverage
- Expanding across care settings
- Ongoing trials and HEOR
Robotic knees drive implants; NPWT ≈10% CAGR; group sales £3.1bn
CORI robotics anchors Smith & Nephew in fast-growing robotics knee arthroplasty and drives implant pull-through. PICO single-use NPWT leads a ≈10% CAGR niche; group sales £3.1bn in 2024. REGENETEN (FDA 2019) covers ~250,000 US repairs/year and OASIS shows broad payer coverage across care settings.
| Product | 2024 metric | Notes | ||
|---|---|---|---|---|
| CORI robotics | Installed base; ASC traction | Robotics knee growth | ||
| PICO NPWT | ≈10% CAGR to 2028; £3.1bn group sales | >10 RCTs; leading share | ||
| REGENETEN / OASIS | ~250k US repairs; broad coverage | Invest RCTs & HEOR |
What is included in the product
Detailed Word Document
Smith & Nephew BCG: Stars (orthopedics) to invest, Cash Cows (wound care) to hold, Question Marks (digital) to evaluate, Dogs to divest.
Customizable Excel Spreadsheet
One-page Smith & Nephew BCG Matrix that clarifies portfolio priorities, eases resource pain points and exports to C-level slides.
Cash Cows
ALLEVYN foam dressings
ALLEVYN sits in the mature, high‑volume foam segment where Smith & Nephew holds entrenched positions and broad formulary access, with clinician preference creating stickiness. Global advanced wound care was ~USD 12.0bn in 2024 with foam growing ~3–4% annually; the Advanced Wound Management portfolio was ~£700m in FY2024, delivering attractive margins and strong cash conversion. Maintain supply excellence and incremental innovation to milk dependable cash flows.
ACTICOAT antimicrobial dressings
Antimicrobial dressings show stable demand and sustain premium pricing. ACTICOAT’s silver technology and clinical lineage underpin a durable share in a mature market, with the global advanced wound care market estimated at about USD 10.5bn in 2024. Marketing intensity is modest relative to returns, so focus on manufacturing efficiency and contracting discipline to optimize cash generation.
IODOSORB/IODOFLEX iodine range
IODOSORB/IODOFLEX iodine gels and dressings address bioburden in chronic wounds and retain long-standing clinical adoption; as of 2024 the category remains established but slow-growing. Smith & Nephew’s franchise continues to be widely specified by clinicians, producing recurring usage patterns that support steady volumes and margins. Optimizing SKU mix and distribution will help sustain reliable free cash flow.
COBLATION ENT tonsil/adenoid
COBLATION ENT tonsil/adenoid lies in a mature procedural market; the COBLATION brand retains strong surgeon familiarity and clinical adoption. Replacement instruments and consumables drive predictable recurring revenue with low promotional needs. Prioritize lifecycle cost management and service quality to protect profitability.
- COBLATION is a Smith & Nephew brand (2024).
- Smith & Nephew reported ~£3.9bn revenue in 2024.
- US tonsillectomy volumes ≈300,000 procedures/year (widely cited).
- Focus on consumable attach rates, service SLAs and cost-to-serve.
LEGION/JOURNEY knee systems
LEGION/JOURNEY knee systems are cash cows for Smith & Nephew: primary and revision knees sit in a mature implant market with ~700,000 US TKAs and ~1.3M global procedures in 2024, and the installed base delivers steady procedure share. Pricing pressure persists, but mix and scale supported cash generation in 2024; focus on inventory turns and standardization preserves margins.
Consumables (wound, knee, ENT) underpin margins; revenue ~£3.9bn
ALLEVYN, ACTICOAT, IODOSORB, COBLATION and LEGION/JOURNEY are cash cows, delivering strong margins and cash conversion within Smith & Nephew’s ~£3.9bn 2024 revenue. Advanced Wound Management was ~£700m in FY2024. Global knees ≈1.3M and US tonsil ≈300k in 2024 underpin steady consumable attach; priorities: supply excellence, SKU rationalization and attach‑rate uplift.
| Product | 2024 metric | Revenue/scale | ||
|---|---|---|---|---|
| Wound | AWM ~£700m | High margin, recurring | Supply | |
| Knees | Global ≈1.3M | Installed base, consumables | Inventory | |
| ENT | US tonsil ≈300k | Predictable consumables | Service |
What You’re Viewing Is Included
Smith & Nephew BCG Matrix
The file you're previewing here is the exact BCG Matrix you'll receive after purchase — no watermarks, no demo content, just a fully formatted, ready-to-use report for strategic clarity. This preview matches the downloadable document and includes market-backed analysis and clear visuals for immediate presentation. After purchase the full file is delivered to your inbox and is editable, printable, and client-ready. Designed by strategy experts, it's ready to plug into business reviews, investor decks, or competitive analyses.
Dogs
Birmingham Hip Resurfacing (MoM)
Birmingham Hip Resurfacing (MoM) has contracted sharply and by 2024 represents under 5% of primary hip procedures in major arthroplasty registries, confined to niche indications. Low market growth plus high competitive and regulatory scrutiny (FDA/EMA and registries through 2024) limits share expansion. The portfolio ties up support with limited returns and higher revision risk, so de‑emphasize or exit selectively.
Legacy GENESIS II knee platform
By 2024 the Legacy GENESIS II knee platform sits in the Dogs quadrant as surgeons shift to newer implant designs and robotic workflows, producing declining procedure volumes. Share is diluted across regions with limited incremental innovation, leaving revenues maintenance-driven and showing low growth. Accelerate platform rationalization and migrate legacy accounts to current Smith & Nephew systems to protect wallet share.
RENASYS reusable NPWT
RENASYS reusable pump NPWT faces mounting pressure from single‑use NPWT and large competitors; 2024 market reports show single‑use NPWT grew ~18% year‑on‑year and captured >50% of new placements. Growth for reusable pumps is tepid and share gains require heavy capex; fleet support and service can erode margins by 10–15%. Pivot resources to single‑use leadership and prune low‑utilization placements.
Legacy arthroscopy towers/cameras
Legacy arthroscopy towers/cameras
Older visualization platforms lag premium competitors in features and ecosystem pull; capital refresh cycles average 7–10 years and 2024 upgrade capture into premium lines is inconsistent, limiting share and growth outside captive accounts. Streamline SKUs and bundle selectively or sunset models where unit economics are unfavorable.- Capital refresh cycles 7–10 years (2024)
- Upgrade capture often <30% in non-captive accounts (2024)
- Share and growth limited outside captive hospitals
- Reduce SKUs, bundle selectively or sunset loss-making SKUs
Commodity wound dressings
Dogs:
Commodity wound dressings
faced intense price competition in 2024, producing low single‑digit margins and little differentiation; volume persists but adds no meaningful growth, so working capital and manufacturing capacity should be redeployed to advanced wound portfolios.- 2024: price compression
- High unit volume, low value
- Release capital & capacity
- Prioritise advanced wound growth
Single‑use NPWT +18% YoY; hip resurfacing <5%; rationalize legacy knees
Birmingham Hip Resurfacing <5% of primary hips (2024). GENESIS II knee volumes declining as surgeons shift to newer implants/robotics. Reusable NPWT losing share to single‑use (~18% YoY; >50% of new placements in 2024). Commodity wound dressings face 2024 price compression and low single‑digit margins; recommend selective exits and redeploy capital.
| Product | 2024 | Action | ||
|---|---|---|---|---|
| BHR MoM | <5% primary hips | Exit/selective | ||
| GENESIS II | Declining; upgrade capture <30% | Rationalize/migrate | ||
| NPWT / Dressings | Single‑use +18% YoY; >50% new; low margins | Pivot to SU; prune dressings |
Question Marks
Extremities (shoulder, hand, foot & ankle)
Extremities implants (shoulder, hand, foot & ankle) are a high‑growth ortho niche—industry forecasts ~6% CAGR to 2028 and rising ASC penetration (US ASCs performed an estimated ~40% of outpatient ortho cases in 2024). Smith & Nephew (FY2024 revenue ~£3.5bn) has room to scale versus incumbents; targeted clinical education and focused sales can accelerate adoption—invest to gain critical mass, notably in total ankle and upper extremity.
Digital surgery & analytics (Real Intelligence)
Planning, intra-op guidance and analytics are expanding rapidly but remain early in penetration; the digital surgery market is growing ~20% CAGR (2024–30) and the installed robotics base surpassed 7,000 systems in 2024. Smith & Nephew’s ecosystem boosts robotics and implant stickiness yet holds a single-digit share today. Demonstrating measurable outcomes (early adopters report 10–20% OR efficiency gains) and prioritizing partnerships, interoperability and evidence are key to conversion to star.
CORI hip/complex recon expansion
CORI hip and complex reconstruction is a Question Mark: robotic workflows beyond knee—hip, partials and revisions—are a fast‑growing adjacency, but robotic hip penetration remained in the single‑digit percent range in 2024, keeping CORI's share modest versus the multi‑billion‑dollar hip arthroplasty market. Software modules and expanded instrument sets can unlock procedure breadth, and targeted R&D plus surgeon training could convert CORI into a second growth engine.
Advanced wound biologics (placental/dermal)
Advanced wound biologics (placental/dermal) are high-growth question marks in 2024 with evolving reimbursement and evidence bases. Smith & Nephew participates but faces fragmented competition and uneven regional access, constraining share. Clinical data and payer alignment in 2024 will determine scale and commercial viability. Invest selectively where proof points and coverage are strongest.
- High-growth segment in 2024
- Fragmented competitive landscape
- Uneven regional reimbursement/access
- Target investments to covered/proven markets
LENS 4K visualization platform
LENS 4K is a Question Mark: next‑gen arthroscopy visualization is growing (market ≈$5.5bn in 2024, ~6% CAGR), yet LENS had a low installed base in 2024 versus entrenched rivals. Bundling with sports‑medicine sets and service contracts can accelerate placements and, if traction improves, reinforce procedure pull‑through and attach rates across the portfolio.
- 2024 market ≈$5.5bn; ~6% CAGR
- LENS low installed base (2024)
- Bundling + service accelerates placements
- Traction → higher attach rates, consumable revenue
Invest in surgical robotics & wound biologics: > 7,000 robots, $5.5bn, ASCs ~40%
Question Marks: extremities, CORI, wound biologics, LENS; SN FY2024 ~£3.5bn. 2024: >7,000 robots; LENS $5.5bn; extremities ~6% CAGR. Action: invest, prove outcomes, align payers; ASCs ~40% (2024).